Diethyldithiocarbamate-Cu4O3 nanocomplex induced mitochondrial and telomerase dysfunction in non-small cell lung

Marwa M Abu-Serie1, María A Blasco2

  • 1Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Egypt.

PubMed
Abstract

Insights

Copper nanocomplexes effectively target non-small cell lung cancer stem cells by inducing cuproptosis and repressing key stemness markers. This promising nanomedicine demonstrates potent tumor-targeting effects with no observed toxicity in animal studies.

Area of Science:

  • Nanomedicine
  • Cancer Research
  • Materials Science

Background:

  • Non-small cell lung cancer (NSCLC) aggressiveness is driven by cancer stem cells (CSCs).
  • Targeting CSCs requires suppressing mediators like mitochondria, aldehyde dehydrogenase (ALDH)1A, and telomere protectors (telomerase reverse transcriptase (TERT) and telomere repeat binding factor (TRF)1).

Purpose of the Study:

  • To develop and evaluate copper nanocomplexes for targeting CSC-mediated NSCLC.
  • To assess the efficacy of diethyldithiocarbamate (DE)-Cu4O3 nanoparticles (NPs) in inducing cuproptosis and repressing CSC markers.

Main Methods:

  • Green chemistry synthesis of DE-Cu4O3 NPs and DE-Cu NPs.
  • Assessment of NP uptake, prooxidant effects, and mitochondrial dysfunction in NSCLC cell lines.
  • Evaluation of inhibition of telomerase, ALDH1A, AKT pathway, and TERT/TRF1 protein levels.
  • In vivo studies in animal models to determine therapeutic effects and toxicity.

Main Results:

  • DE-Cu4O3 NPs exhibited superior growth inhibition of NSCLC spheroids compared to DE-Cu NPs.
  • DE-Cu4O3 NPs showed higher uptake, induced significant mitochondrial dysfunction (reduced membrane potential and DNA copy number), and strongly inhibited telomerase and ALDH1A.
  • Redox imbalance and suppressed AKT pathway led to decreased TERT and TRF1, collapsing telomeres.
  • Animal studies confirmed potent, selective tumor-targeting effects of DE-Cu4O3 nanocomplexes with no observed toxicity.

Conclusions:

  • DE-Cu4O3 nanocomplex demonstrates significant potential as a nanomedicine for NSCLC treatment.
  • The mechanism involves cuproptosis induction and suppression of CSC markers and telomere maintenance pathways.